SCHEMBL7675754

SCHEMBL7675754

NNC(=O)c1[nH]c2ccc(F)cc2c1-c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 3/20 0.74
KDM4E B2RXH2 3/20 0.73
ALDH1A1 P00352 3/20 0.73
GAA P10253 2/20 0.73
MAPT P10636 2/20 0.73
CA12 O43570 1/20 0.68
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
CA4 P22748 1/20 0.68
CA6 P23280 1/20 0.68
CA5A P35218 1/20 0.68
CA7 P43166 1/20 0.68
CA9 Q16790 1/20 0.68
CA14 Q9ULX7 1/20 0.68
CA5B Q9Y2D0 1/20 0.68
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24074569 0.87 MAP2 (0.70) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL215430 0.85 MAP2 (1.00) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL215691 0.85 MAP2 (0.79) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL6842213 0.84 MEN1 (0.73) KDM4EALDH1A1GAAMAPTCA12
SCHEMBL7560999 0.84 ALDH1A1 (1.00) KDM4EALDH1A1GAAMAPTCA12
SCHEMBL2735926 0.84 MAP2 (0.62) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL7677920 0.84 GAA (0.79) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL7566685 0.83 GAA (1.00) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL2735915 0.83 MAP2 (0.61) MAP2KDM4EALDH1A1GAAMAPT
SCHEMBL14304852 0.82 MAP2 (0.75) MAP2KDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAP2 1547/4885KDM4E 1608/4885ALDH1A1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.